PMID- 27091471
OWN - NLM
STAT- MEDLINE
DCOM- 20170309
LR  - 20211204
IS  - 1865-3774 (Electronic)
IS  - 0925-5710 (Linking)
VI  - 104
IP  - 2
DP  - 2016 Aug
TI  - Biomarkers for predicting clinical response to immunosuppressive therapy in 
      aplastic anemia.
PG  - 153-8
LID - 10.1007/s12185-016-2009-z [doi]
AB  - The decision to select hematopoietic stem cell transplantation (HSCT) or 
      immunosuppressive therapy (IST) as initial therapy in acquired aplastic anemia 
      (AA) is currently based on patient age and the availability of a human leukocyte 
      antigen (HLA)-matched donor. Although IST is a promising treatment option, the 
      ability to predict its long-term outcomes remains poor due to refractoriness, 
      relapses, and the risk of clonal evolution. Several predictive biomarkers for 
      response to IST have been posited, including age, gender, pre-treatment blood 
      cell counts, cytokines, gene mutations, paroxysmal nocturnal hemoglobinuria 
      (PNH), and telomere length (TL). While previous studies have provided substantial 
      biological insights into the utility of IST, the prognostic power of the reported 
      biomarkers is currently insufficient to contribute to clinical decision making. 
      Recently, a large retrospective analysis proposed the combination of minor PNH 
      clones and TL as an efficient predictor of IST response. Identification of a 
      reliable predictor would provide a useful tool for determining the most 
      appropriate treatment choice for AA patients, including up-front HSCT from 
      HLA-matched unrelated donor. The present review summarizes studies evaluating the 
      utility of biomarkers in predicting the clinical response to IST of patients with 
      AA, and provides a baseline for prospective studies aimed at validating 
      previously reported biomarkers.
FAU - Narita, Atsushi
AU  - Narita A
AD  - Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 
      Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8650, Japan.
FAU - Kojima, Seiji
AU  - Kojima S
AD  - Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 
      Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8650, Japan. 
      kojimas@med.nagoya-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160418
PL  - Japan
TA  - Int J Hematol
JT  - International journal of hematology
JID - 9111627
RN  - 0 (Biomarkers)
SB  - IM
MH  - Anemia, Aplastic/*therapy
MH  - Biomarkers/*analysis
MH  - Humans
MH  - Immunosuppression Therapy/*methods
MH  - Prognosis
OTO - NOTNLM
OT  - Aplastic anemia
OT  - Immunosuppressive therapy
OT  - Paroxysmal nocturnal hemoglobinuria
OT  - Prognosis
OT  - Telomere length
EDAT- 2016/04/20 06:00
MHDA- 2017/03/10 06:00
CRDT- 2016/04/20 06:00
PHST- 2016/03/09 00:00 [received]
PHST- 2016/04/06 00:00 [accepted]
PHST- 2016/04/06 00:00 [revised]
PHST- 2016/04/20 06:00 [entrez]
PHST- 2016/04/20 06:00 [pubmed]
PHST- 2017/03/10 06:00 [medline]
AID - 10.1007/s12185-016-2009-z [pii]
AID - 10.1007/s12185-016-2009-z [doi]
PST - ppublish
SO  - Int J Hematol. 2016 Aug;104(2):153-8. doi: 10.1007/s12185-016-2009-z. Epub 2016 
      Apr 18.